This medication is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. These mechanisms lead to improved fasting and postprandial blood glucose control.
Recommended for patients:
– with type 2 diabetes insufficiently controlled by diet and exercise
– requiring improved HbA1c management
– seeking an oral alternative to injectable GLP-1 therapies
The efficacy and safety of semaglutide have been demonstrated in the international PIONEER clinical trial program, showing significant HbA1c reduction, sustained glycemic control, and a favorable safety profile during long-term use.
Indicated for the treatment of type 2 diabetes mellitus in adults. Used to lower blood glucose levels, enhance insulin sensitivity, and maintain stable metabolic control through incretin-based mechanisms.
The medication is taken orally once daily on an empty stomach with a small amount of water. Patients should wait at least 30 minutes before eating, drinking, or taking other oral medications. Dosage and treatment duration are determined by a healthcare professional.
Contraindications
– hypersensitivity to semaglutide
– type 1 diabetes mellitus
– diabetic ketoacidosis
– history of medullary thyroid carcinoma
– multiple endocrine neoplasia syndrome type 2
– pregnancy and breastfeeding
Side effects
– nausea
– vomiting
– diarrhea or constipation
– abdominal pain
– decreased appetite
– headache
– potential hypoglycemia when combined with other antidiabetic agents
